RxDoctor Payments Data

Beomseok Oh, NP

Family · New York, NYNPI 1194197921

Payments from drug & device makers

$599in general payments, 2019–2025

Across 39 payments — averaging $15.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Exact Sciences$112
  • Gilead$86
  • GSK$75
  • Pfizer$73
  • Sanofi-aventis U.S. LLC$55
  • Genentech USA, Inc.$40
  • plus $158 from 7 others

What the payments were for

  • Food & beverage$599100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$599 in reported general payments places this provider in the 60th percentile of 8,883 family providers in New York.

See all family providers in New York

Medicare billing

Part B allowed, 2024
$37,710
Medicare patients
128
Services billed
560

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate35$46,990
JardianceEmpagliflozin32$44,999
OzempicSemaglutide19$20,755
LinzessLinaclotide30$20,491
Trelegy ElliptaFluticasone/Umeclidin/Vilanter28$17,750
JanumetSitagliptin Phos/Metformin Hcl12$16,349
EliquisApixaban27$15,721
TrulicityDulaglutide13$14,075
MounjaroTirzepatide12$12,560
SymbicortBudesonide/Formoterol Fumarate24$5,931
VascepaIcosapent Ethyl12$5,608
Breo ElliptaFluticasone/Vilanterol13$4,973
Diclofenac Sodium58$4,749
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog13$3,768
Atorvastatin Calcium311$3,387

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$26$44,99932 claims
Lilly USA, LLCTrulicity, Mounjaro$34$26,63425 claims
GSKTrelegy Ellipta, Breo Ellipta$75$22,72341 claims
PfizerEliquis$73$15,72127 claims
Sanofi-aventis U.S. LLCLantus$55$79214 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 8,883 family providers in New York.

Other family in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →